Muenchensteinerstrasse 38
Basel 4002
Switzerland
41 61 316 81 11
https://www.lonza.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 16,218
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Pierre-Alain Ruffieux Ph.D. | Chief Exec. Officer | 2.63M | N/A | 1969 |
Mr. Philippe Deecke | Chief Financial Officer | N/A | N/A | 1972 |
Mr. Stefan Stoffel | Head of Group Operations | N/A | N/A | 1966 |
Mr. Dirk Oehlers | VP of Investor Relations | N/A | N/A | N/A |
Mr. Andreas Bohrer | Group Gen. Counsel & Company Sec. | N/A | N/A | N/A |
Ms. Victoria Morgan | Head of External Communications | N/A | N/A | N/A |
Ms. Jennifer Clancy | Sr. Director of Global Marketing | N/A | N/A | N/A |
Ms. Caroline Barth | Chief HR Officer | N/A | N/A | 1972 |
Ms. Constance Ward | Head of External Communications | N/A | N/A | N/A |
Dr. Sanna Fowler | Head of External Communications | N/A | N/A | N/A |
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Lonza Group Ltd’s ISS governance QualityScore as of 1 May 2022 is 1. The pillar scores are Audit: 5; Board: 1; Shareholder rights: 1; Compensation: 2.